<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01316419</url>
  </required_header>
  <id_info>
    <org_study_id>1235.42</org_study_id>
    <nct_id>NCT01316419</nct_id>
  </id_info>
  <brief_title>Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension</brief_title>
  <official_title>An Observational Study to Evaluate the Effects of Twynsta Tablets (Telmisartan and Amlodipine FDC, q.d.) With Life Style Modifications on Blood Pressure, Quality of Life, and Other Risk Factors in Korean Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This observational study is designed to evaluate the effects of Twynsta tablets with life
      style modifications on blood pressure, quality of life, and other risk factors in Korean
      patients with hypertension in a routine clinical practice setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Blood Pressure Change Systolic Blood Pressure (SBP) From Baseline After 24±2 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>The primary endpoint is the mean blood pressure change SBP from baseline after 24±2 weeks of treatment or at the last observation in case of early withdrawal.
Baseline is defined as data collected on baseline visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Blood Pressure Change Diastolic Blood Pressure (DBP) From Baseline After 24±2 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>The primary endpoint is the mean blood pressure change DBP from baseline after 24±2 weeks of treatment or at the last observation in case of early withdrawal.
Baseline is defined as data collected on baseline visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Target Blood Pressure SBP/DBP &lt;140/90 mmHg.</measure>
    <time_frame>24±2 weeks</time_frame>
    <description>Percentage of patients achieving target blood pressure SBP/DBP &lt;140/90 mmHg is a key secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving DBP Response</measure>
    <time_frame>24±2 weeks</time_frame>
    <description>Percentage of patients achieving DBP response (defined as mean seated DBP &lt; 90 mmHg or a drop of ≥ 10 mmHg) is a key secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving SBP Response</measure>
    <time_frame>24±2 weeks</time_frame>
    <description>Percentage of patients achieving SBP response (defined as mean seated SBP &lt; 140 mmHg or a drop of ≥ 10 mmHg) is a key secondary endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Physical Health Domain</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Psychological Domain</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Social Relationships Domain</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Environment Domain</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Overall</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol (EQ) Visual Analogue Scale (VAS)</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'best imaginable health state' and 'worst imaginable health state. The scale goes from 0 to 100, a low value shows better physical health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving SBP/DBP &lt; 130/80 mmHg Among Patients With Diabetes or Kidney Disease</measure>
    <time_frame>24±2 weeks</time_frame>
    <description>Percentage of patients achieving SBP/DBP &lt; 130/80 mmHg among patients with diabetes or kidney disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Lipid Change - Low Density Lipoprotein (LDL)-Cholesterol</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>Mean blood lipid change from baseline - low density lipoprotein (LDL)-Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Lipid Change - High Density Lipoprotein (HDL)-Cholesterol</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>Mean blood lipid change from baseline - high density lipoprotein (HDL)-Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Lipid Change - Triglyceride</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>Mean blood lipid change - Triglyceride</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Lipid Change - Total Cholesterol</measure>
    <time_frame>baseline and 24±2 weeks</time_frame>
    <description>Mean blood lipid change - Total Cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Normal Body Mass Index (BMI)</measure>
    <time_frame>24±2 weeks</time_frame>
    <description>Percentage of patients achieving normal BMI (18.5 kg/sq.m to 24.9 kg/sq.m) are presented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 12±2 Weeks</measure>
    <time_frame>12±2 weeks</time_frame>
    <description>Percentage of patients who complied with each category of lifestyle modification recommendations at 12±2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 24±2 Weeks</measure>
    <time_frame>24±2 weeks</time_frame>
    <description>Percentage of patients who complied with each category of lifestyle modification recommendations at 12±2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Reported Adverse Events.</measure>
    <time_frame>24±2 weeks</time_frame>
    <description>Incidence as per the severity of reported adverse events is presented.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2089</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Patients with essential hypertension</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan 40mg or 80mg</description>
    <arm_group_label>Patients with essential hypertension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
    <description>amlodipine 5mg or 10mg</description>
    <arm_group_label>Patients with essential hypertension</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Korean
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients with essential hypertension whose blood pressure is not adequately controlled
             by amlodipine or telmisartan monotherapy (=140/90 mmHg, = 130/80 mmHg for those with
             diabetes or kidney disease)

          2. Age = 19 years at enrollment

          3. Male or female patient (or legally acceptable representative) willing and able to
             provide written informed consent

        Exclusion criteria:

          1. Patients with previous exposure to Twynsta

          2. Patients with hypersensitivity to the active substances, or to dihydropyridine
             derivatives

          3. Female patients at second and third trimesters of pregnancy

          4. Female patients with lactation

          5. Patients with biliary obstructive disorders

          6. Patients with severe hepatic impairment

          7. Patients with high grade aortic stenosis

          8. Patients with shock

          9. Patients with hereditary conditions such as intolerance with excipient of the products

         10. Current participation in other clinical trials or observational studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 15</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 37</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 42</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 55</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 54</name>
      <address>
        <city>Chonbuk</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 18</name>
      <address>
        <city>Chonnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 48</name>
      <address>
        <city>Chungcheong</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 17</name>
      <address>
        <city>Chungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 19</name>
      <address>
        <city>Chungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 8</name>
      <address>
        <city>Chungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 46</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 31</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 39</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 40</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 41</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 45</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 14</name>
      <address>
        <city>Deagu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 25</name>
      <address>
        <city>Deagu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 26</name>
      <address>
        <city>Deagu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 44</name>
      <address>
        <city>Gangwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 24</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 32</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 5</name>
      <address>
        <city>Gyeonggi do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 11</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 13</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 16</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 21</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 23</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 30</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 43</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 47</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 6</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 9</name>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 35</name>
      <address>
        <city>Gyeongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 51</name>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 52</name>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 12</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 1</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 20</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 22</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 27</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 28</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 29</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 2</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 33</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 34</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 36</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 38</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 3</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 49</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 4</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 50</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 53</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 7</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site 10</name>
      <address>
        <city>Ulan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>March 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <results_first_submitted>June 26, 2015</results_first_submitted>
  <results_first_submitted_qc>June 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2015</results_first_posted>
  <last_update_submitted>September 8, 2015</last_update_submitted>
  <last_update_submitted_qc>September 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is an observational study to evaluate the effects of Twynsta tablets (Telmisartan and amlodipine fixed dose combination (FDC), once daily (q.d.)) with life style modifications on blood pressure, quality of life, and other risk factors in Korean patients with hypertension</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
          <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2089"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1824"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="265"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violated inclusion/exclusion criterion</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated patients fulfilling the inclusion-exclusion criterias and who have completed the follow-up visits of the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
          <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1824"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.65" spread="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Blood Pressure Change Systolic Blood Pressure (SBP) From Baseline After 24±2 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.</title>
        <description>The primary endpoint is the mean blood pressure change SBP from baseline after 24±2 weeks of treatment or at the last observation in case of early withdrawal.
Baseline is defined as data collected on baseline visit.</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Pressure Change Systolic Blood Pressure (SBP) From Baseline After 24±2 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.</title>
          <description>The primary endpoint is the mean blood pressure change SBP from baseline after 24±2 weeks of treatment or at the last observation in case of early withdrawal.
Baseline is defined as data collected on baseline visit.</description>
          <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.81" spread="16.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mean SBP change from baseline at the last visit will be analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Target Blood Pressure SBP/DBP &lt;140/90 mmHg.</title>
        <description>Percentage of patients achieving target blood pressure SBP/DBP &lt;140/90 mmHg is a key secondary endpoint.</description>
        <time_frame>24±2 weeks</time_frame>
        <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Target Blood Pressure SBP/DBP &lt;140/90 mmHg.</title>
          <description>Percentage of patients achieving target blood pressure SBP/DBP &lt;140/90 mmHg is a key secondary endpoint.</description>
          <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving DBP Response</title>
        <description>Percentage of patients achieving DBP response (defined as mean seated DBP &lt; 90 mmHg or a drop of ≥ 10 mmHg) is a key secondary endpoint.</description>
        <time_frame>24±2 weeks</time_frame>
        <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving DBP Response</title>
          <description>Percentage of patients achieving DBP response (defined as mean seated DBP &lt; 90 mmHg or a drop of ≥ 10 mmHg) is a key secondary endpoint.</description>
          <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Blood Pressure Change Diastolic Blood Pressure (DBP) From Baseline After 24±2 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.</title>
        <description>The primary endpoint is the mean blood pressure change DBP from baseline after 24±2 weeks of treatment or at the last observation in case of early withdrawal.
Baseline is defined as data collected on baseline visit.</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Pressure Change Diastolic Blood Pressure (DBP) From Baseline After 24±2 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.</title>
          <description>The primary endpoint is the mean blood pressure change DBP from baseline after 24±2 weeks of treatment or at the last observation in case of early withdrawal.
Baseline is defined as data collected on baseline visit.</description>
          <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.48" spread="11.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mean DBP change from baseline at the last visit will be analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving SBP Response</title>
        <description>Percentage of patients achieving SBP response (defined as mean seated SBP &lt; 140 mmHg or a drop of ≥ 10 mmHg) is a key secondary endpoint.</description>
        <time_frame>24±2 weeks</time_frame>
        <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving SBP Response</title>
          <description>Percentage of patients achieving SBP response (defined as mean seated SBP &lt; 140 mmHg or a drop of ≥ 10 mmHg) is a key secondary endpoint.</description>
          <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1662"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Physical Health Domain</title>
        <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>Patients with a baseline and an endpoint WHOQOL-BREF response</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Physical Health Domain</title>
          <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
          <population>Patients with a baseline and an endpoint WHOQOL-BREF response</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1099</p_value>
            <p_value_desc>The change of QOL data collected using the WHOQOL-BREF is analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Psychological Domain</title>
        <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Psychological Domain</title>
          <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
          <population>All patients with a baseline and an endpoint blood pressure measurement.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0197</p_value>
            <p_value_desc>The change of QOL data collected using the WHOQOL-BREF is analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Social Relationships Domain</title>
        <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>Patients with a baseline and an endpoint WHOQOL-BREF response</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Social Relationships Domain</title>
          <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
          <population>Patients with a baseline and an endpoint WHOQOL-BREF response</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4543</p_value>
            <p_value_desc>The change of QOL data collected using the WHOQOL-BREF is analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Environment Domain</title>
        <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>Patients with a baseline and an endpoint WHOQOL-BREF response</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Environment Domain</title>
          <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
          <population>Patients with a baseline and an endpoint WHOQOL-BREF response</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0152</p_value>
            <p_value_desc>The change of QOL data collected using the WHOQOL-BREF is analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Overall</title>
        <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>Patients with a baseline and an endpoint WHOQOL-BREF response</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Overall</title>
          <description>WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.
The Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.</description>
          <population>Patients with a baseline and an endpoint WHOQOL-BREF response</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1490"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <p_value_desc>The change of QOL data collected using the WHOQOL-BREF is analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQol (EQ) Visual Analogue Scale (VAS)</title>
        <description>The EQ VAS records the respondent’s self-rated health on a vertical, visual analogue scale where the endpoints are labelled ‘best imaginable health state’ and ‘worst imaginable health state. The scale goes from 0 to 100, a low value shows better physical health.</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>Patients with a baseline and an endpoint EQ VAS response</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQol (EQ) Visual Analogue Scale (VAS)</title>
          <description>The EQ VAS records the respondent’s self-rated health on a vertical, visual analogue scale where the endpoints are labelled ‘best imaginable health state’ and ‘worst imaginable health state. The scale goes from 0 to 100, a low value shows better physical health.</description>
          <population>Patients with a baseline and an endpoint EQ VAS response</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread="16.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The change of QOL data collected using the EQ VAS is analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving SBP/DBP &lt; 130/80 mmHg Among Patients With Diabetes or Kidney Disease</title>
        <description>Percentage of patients achieving SBP/DBP &lt; 130/80 mmHg among patients with diabetes or kidney disease</description>
        <time_frame>24±2 weeks</time_frame>
        <population>All patients with diabetes, kidney disease or both (diabetes + kidney disease)</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving SBP/DBP &lt; 130/80 mmHg Among Patients With Diabetes or Kidney Disease</title>
          <description>Percentage of patients achieving SBP/DBP &lt; 130/80 mmHg among patients with diabetes or kidney disease</description>
          <population>All patients with diabetes, kidney disease or both (diabetes + kidney disease)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diabetes (N=269)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kidney Disease (N=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes + Kidney disease (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Lipid Change - Low Density Lipoprotein (LDL)-Cholesterol</title>
        <description>Mean blood lipid change from baseline - low density lipoprotein (LDL)-Cholesterol</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Lipid Change - Low Density Lipoprotein (LDL)-Cholesterol</title>
          <description>Mean blood lipid change from baseline - low density lipoprotein (LDL)-Cholesterol</description>
          <population>Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.17" spread="29.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Mean LDL-C change from baseline at the last visit will be analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Lipid Change - High Density Lipoprotein (HDL)-Cholesterol</title>
        <description>Mean blood lipid change from baseline - high density lipoprotein (HDL)-Cholesterol</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Lipid Change - High Density Lipoprotein (HDL)-Cholesterol</title>
          <description>Mean blood lipid change from baseline - high density lipoprotein (HDL)-Cholesterol</description>
          <population>Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4248</p_value>
            <p_value_desc>Mean HDL-C change from baseline at the last visit will be analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Lipid Change - Triglyceride</title>
        <description>Mean blood lipid change - Triglyceride</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Lipid Change - Triglyceride</title>
          <description>Mean blood lipid change - Triglyceride</description>
          <population>Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.76" spread="74.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5579</p_value>
            <p_value_desc>Mean Triglyceride change from baseline at the last visit will be analyzed by paired t-test</p_value_desc>
            <method>Paired t test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Lipid Change - Total Cholesterol</title>
        <description>Mean blood lipid change - Total Cholesterol</description>
        <time_frame>baseline and 24±2 weeks</time_frame>
        <population>Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Lipid Change - Total Cholesterol</title>
          <description>Mean blood lipid change - Total Cholesterol</description>
          <population>Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.62" spread="30.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Mean total cholesterol change from baseline at the last visit will be analyzed by paired t-test</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Normal Body Mass Index (BMI)</title>
        <description>Percentage of patients achieving normal BMI (18.5 kg/sq.m to 24.9 kg/sq.m) are presented</description>
        <time_frame>24±2 weeks</time_frame>
        <population>Patients with a baseline and an endpoint BMI together with evaluation record on recommendations for lifestyle modifications.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Normal Body Mass Index (BMI)</title>
          <description>Percentage of patients achieving normal BMI (18.5 kg/sq.m to 24.9 kg/sq.m) are presented</description>
          <population>Patients with a baseline and an endpoint BMI together with evaluation record on recommendations for lifestyle modifications.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1392"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 12±2 Weeks</title>
        <description>Percentage of patients who complied with each category of lifestyle modification recommendations at 12±2 weeks</description>
        <time_frame>12±2 weeks</time_frame>
        <population>Patients with a baseline and an endpoint BMI together with evaluation record on recommendations for lifestyle modifications.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 12±2 Weeks</title>
          <description>Percentage of patients who complied with each category of lifestyle modification recommendations at 12±2 weeks</description>
          <population>Patients with a baseline and an endpoint BMI together with evaluation record on recommendations for lifestyle modifications.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1646"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Well balanced diet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dietary sodium reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderation of alcohol consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 24±2 Weeks</title>
        <description>Percentage of patients who complied with each category of lifestyle modification recommendations at 12±2 weeks</description>
        <time_frame>24±2 weeks</time_frame>
        <population>Patients with a baseline and an endpoint BMI together with evaluation record on recommendations for lifestyle modifications.</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 24±2 Weeks</title>
          <description>Percentage of patients who complied with each category of lifestyle modification recommendations at 12±2 weeks</description>
          <population>Patients with a baseline and an endpoint BMI together with evaluation record on recommendations for lifestyle modifications.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1514"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Well balanced diet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dietary sodium reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderation of alcohol consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence and Severity of Reported Adverse Events.</title>
        <description>Incidence as per the severity of reported adverse events is presented.</description>
        <time_frame>24±2 weeks</time_frame>
        <population>Patients having received at least one dose of Twynsta tablets</population>
        <group_list>
          <group group_id="O1">
            <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
            <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Reported Adverse Events.</title>
          <description>Incidence as per the severity of reported adverse events is presented.</description>
          <population>Patients having received at least one dose of Twynsta tablets</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1824"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events occurring during the course of the observational study (i.e., from signing the informed consent onwards through the observational phase); Up to 24±2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Twynsta (Telmisartan and Amlodipine FDC) Tablets</title>
          <description>Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Fibromatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1824"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1824"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

